Neo-Adjuvant Treatment in Primary Resectable Pancreatic Cancer: A Systematic Review and PRISMA-Compliant Updated Metanalysis of Oncological Outcomes.
Raffaello RoeselLetizia DeantonioLorenzo BernardiMaria Luisa GaroPietro Majno-HurstAlberto VannelliMarco CefalìMaria Celeste PalmarocchiMaria Carla ValliGuido PesolaAlessandra CristaudiSara De DossoPublished in: Cancers (2023)
NAT is associated with improved survival for patients with resectable pancreatic adenocarcinoma; however, the optimal treatment strategy has yet to be defined, and further studies are required.